Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.500
-0.120 (-3.31%)
At close: Mar 6, 2026, 4:00 PM EST
3.490
-0.010 (-0.29%)
After-hours: Mar 6, 2026, 7:28 PM EST
Ironwood Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Ironwood Pharmaceuticals stock have an average target of 4.94, with a low estimate of 0.70 and a high estimate of 10. The average target predicts an increase of 41.14% from the current stock price of 3.50.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Ironwood Pharmaceuticals stock from 5 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +185.71% | Feb 26, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $3 → $5 | Hold | Maintains | $3 → $5 | +42.86% | Jan 5, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $8 | Hold → Buy | Upgrades | $8 | +128.57% | Jan 5, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $1 → $3 | Hold | Maintains | $1 → $3 | -14.29% | Nov 11, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $7 → $1 | Buy → Hold | Downgrades | $7 → $1 | -71.43% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
467.77M
from 296.15M
Increased by 57.95%
Revenue Next Year
488.30M
from 467.77M
Increased by 4.39%
EPS This Year
1.18
from 0.15
Increased by 693.88%
EPS Next Year
1.34
from 1.18
Increased by 13.85%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 486.9M | 516.1M | |||
| Avg | 467.8M | 488.3M | |||
| Low | 442.9M | 457.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 64.4% | 10.3% | |||
| Avg | 57.9% | 4.4% | |||
| Low | 49.6% | -2.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.22 | 1.40 | |||
| Avg | 1.18 | 1.34 | |||
| Low | 1.13 | 1.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 720.8% | 18.5% | |||
| Avg | 693.9% | 13.9% | |||
| Low | 659.4% | 8.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.